CTOs on the Move

Boundless Bio

www.boundlessbio.com

 
Boundless Bio, a San Diego based company backed by ARCH Venture Partners, is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.boundlessbio.com
  • 11099 North Torrey Pines Road Suite 280
    La Jolla, CA USA 92037
  • Phone: 858.766.9912

Executives

Name Title Contact Details
Jason Christiansen
 Chief Technology Officer Profile

Funding

Boundless Bio raised $46.4M on 09/19/2019
Boundless Bio raised $105M on 04/28/2021

Similar Companies

Hummingbird Bioscience

Precision Medicine. Precision Therapies.Hummingbird Bioscience is leading a bold new way of engineering precision biotherapeutics that can define the future of precision medicine. We focus on important biologically validated targets in cancer and autoi...

Alfa Wassermann

Alfa Wassermann, Inc. is a West Caldwell, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

braunmedical

braunmedical is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Goodwin Biotechnology

Goodwin Biotechnology is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Personalis

Personalis, Inc. is partnering with biopharma to develop and commercialize the next generation of cancer immunotherapies. We provide advanced genomic sequencing and analytics for immuno-oncology. Our patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products and makes it possible for us to achieve augmented coverage of difficult-to-sequence genomic regions often missed with the use of conventional sequencing techniques, for more comprehensive and accurate genomic data. ACE ImmunoID, our universal platform for immuno-oncology, combines augmented whole exome and transcriptome assays with analytics that capture neoantigens, elucidate the tumor microenviroment, and identify mechanisms of tumor escape.